Vifor Drops CV Endpoints In Phase IIIb Veltassa Study After COVID-19 Impacts

Ex-GSK Abbas Hussain Appointed CEO

Vifor Pharma is still hoping for further clinical data to help differentiate its potassium binder Veltassa in the competitive hyperkalemia market after recruitment into its Phase IIIb DIAMOND study was slowed by COVID-19-related changes to clinical practice, necessitating a new primary endpoint.  

St Gallen, Switzerland
St Gallen, Switzerland, Where Vifor Pharma Is Based • Source: Alamy

COVID-related revisions to a high-profile Veltassa Phase IIIb trial, and the appointment of a new CEO, ex-GSK executive Abbas Hussain, have punctuated the week at Switzerland’s specialty company, Vifor Pharma Group , which is aiming to build its presence in the cardio-renal space that is also being targeted by other companies. 

Vifor announced on 24 June that it was changing the primary endpoint in its much-anticipated Phase IIIb DIAMOND study involving...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Former Moderna Exec Launches Company Focused On mRNA Despite HHS Funding Cuts

 
• By 

Emerging Company Profile: Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.

Nicox Plots US Submission After Another Phase III Glaucoma Win

 
• By 

The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.

Rocket’s Warp Drive Back Online As FDA Lifts Danon Gene Therapy Hold

 

The company took a prophylactic C3 inhibitor out of the immunomodulatory regimen used in its Phase II study of RP-A501, lowered the dose and adjusted its use of eculizumab.